Search Results
Search for other papers by Philip Newsholme in
Google Scholar
PubMed
Search for other papers by Vinicius Cruzat in
Google Scholar
PubMed
Search for other papers by Frank Arfuso in
Google Scholar
PubMed
Search for other papers by Kevin Keane in
Google Scholar
PubMed
manifestations of the metabolic syndrome. Glucose, the body's primary metabolic fuel source, is ingested usually in polymeric form following the consumption of a mixed meal, and the subsequent postprandial elevation in blood glucose level is stringently modulated
Search for other papers by Laura D Brown in
Google Scholar
PubMed
metabolic syndrome and type 2 diabetes ( Barker et al . 2002 , Whincup et al . 2008 , Atlantis et al . 2009 ), and risk of cardiovascular events later in life ( Basaria & Bhasin 2012 ). Thus, suppressed development of muscle in IUGR fetuses could be a
Novo Nordisk Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia
Search for other papers by Keld Fosgerau in
Google Scholar
PubMed
Novo Nordisk Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia
Search for other papers by Christian Fledelius in
Google Scholar
PubMed
Novo Nordisk Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia
Search for other papers by Kent E Pedersen in
Google Scholar
PubMed
Novo Nordisk Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia
Search for other papers by Jesper B Kristensen in
Google Scholar
PubMed
Novo Nordisk Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia
Search for other papers by Jens R Daugaard in
Google Scholar
PubMed
Novo Nordisk Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia
Search for other papers by Miguel A Iglesias in
Google Scholar
PubMed
Novo Nordisk Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia
Search for other papers by Edward W Kraegen in
Google Scholar
PubMed
Novo Nordisk Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia
Search for other papers by Stuart M Furler in
Google Scholar
PubMed
Introduction It is now apparent that disturbances in lipid metabolism contribute significantly to insulin resistance and other aspects of the metabolic syndrome. The tissues that primarily determine the whole-body glucose homeostasis
Search for other papers by Anna H Kongsted in
Google Scholar
PubMed
Search for other papers by Sanne V Husted in
Google Scholar
PubMed
Search for other papers by Malin P Thygesen in
Google Scholar
PubMed
Search for other papers by Vibeke G Christensen in
Google Scholar
PubMed
Search for other papers by Dominique Blache in
Google Scholar
PubMed
Search for other papers by Anders Tolver in
Google Scholar
PubMed
Search for other papers by Torben Larsen in
Google Scholar
PubMed
Search for other papers by Bjørn Quistorff in
Google Scholar
PubMed
Search for other papers by Mette O Nielsen in
Google Scholar
PubMed
Introduction The prevalence of metabolic syndrome and type 2 diabetes (T2D) is increasing in an epidemic-like fashion, and it is particularly pronounced in developing countries currently undergoing rapid economic transition and experiencing
Search for other papers by Elena Maneschi in
Google Scholar
PubMed
Search for other papers by Linda Vignozzi in
Google Scholar
PubMed
Search for other papers by Annamaria Morelli in
Google Scholar
PubMed
Search for other papers by Tommaso Mello in
Google Scholar
PubMed
Search for other papers by Sandra Filippi in
Google Scholar
PubMed
Search for other papers by Ilaria Cellai in
Google Scholar
PubMed
Search for other papers by Paolo Comeglio in
Google Scholar
PubMed
Search for other papers by Erica Sarchielli in
Google Scholar
PubMed
Search for other papers by Alessandra Calcagno in
Google Scholar
PubMed
Search for other papers by Benedetta Mazzanti in
Google Scholar
PubMed
Search for other papers by Roberto Vettor in
Google Scholar
PubMed
Search for other papers by Gabriella Barbara Vannelli in
Google Scholar
PubMed
Search for other papers by Luciano Adorini in
Google Scholar
PubMed
Search for other papers by Mario Maggi in
Google Scholar
PubMed
Introduction The metabolic syndrome (MetS) is a constellation of metabolic abnormalities centered on insulin resistance and visceral fat accumulation. In addition to insulin resistance and visceral obesity, MetS is accompanied by dyslipidemia with
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Iwona J Bujalska in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Omar M Durrani in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Joseph Abbott in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Claire U Onyimba in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Pamela Khosla in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Areeb H Moosavi in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Tristan T Q Reuser in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Paul M Stewart in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Jeremy W Tomlinson in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Elizabeth A Walker in
Google Scholar
PubMed
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham,
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QU, UK
Search for other papers by Saaeha Rauz in
Google Scholar
PubMed
), ocular surface renewal ( Onyimba et al. 2006 ), inflammation ( Thieringer et al. 2001 , Zhang et al. 2005 ) and the metabolic syndrome – a cluster of cardiovascular risk factors, including hypertension, obesity, hyperlipidaemia and insulin
Search for other papers by I J Bujalska in
Google Scholar
PubMed
Search for other papers by L L Gathercole in
Google Scholar
PubMed
Search for other papers by J W Tomlinson in
Google Scholar
PubMed
Search for other papers by C Darimont in
Google Scholar
PubMed
Search for other papers by J Ermolieff in
Google Scholar
PubMed
Search for other papers by A N Fanjul in
Google Scholar
PubMed
Search for other papers by P A Rejto in
Google Scholar
PubMed
Search for other papers by P M Stewart in
Google Scholar
PubMed
metabolic syndrome (MS). However, Cushing's syndrome is rare and circulating glucocorticoid levels are usually normal or even slightly reduced in obese patients ( Fraser et al . 1999 ). At a cellular level, glucocorticoids within human adipose tissue
Search for other papers by Irene Andrés-Blasco in
Google Scholar
PubMed
Search for other papers by Andrea Herrero-Cervera in
Google Scholar
PubMed
Search for other papers by Ángela Vinué in
Google Scholar
PubMed
Institute of Health Research-INCLIVA, Endocrinology and Nutrition Department Clinic Hospital and Department of Medicine, CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Department of Farmacology, Centro de Investigación Príncipe Felipe, Avenida Menéndez Pelayo, 4, 46010 Valencia, Spain
Institute of Health Research-INCLIVA, Endocrinology and Nutrition Department Clinic Hospital and Department of Medicine, CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Department of Farmacology, Centro de Investigación Príncipe Felipe, Avenida Menéndez Pelayo, 4, 46010 Valencia, Spain
Search for other papers by Sergio Martínez-Hervás in
Google Scholar
PubMed
Search for other papers by Laura Piqueras in
Google Scholar
PubMed
Institute of Health Research-INCLIVA, Endocrinology and Nutrition Department Clinic Hospital and Department of Medicine, CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Department of Farmacology, Centro de Investigación Príncipe Felipe, Avenida Menéndez Pelayo, 4, 46010 Valencia, Spain
Search for other papers by María Jesús Sanz in
Google Scholar
PubMed
Institute of Health Research-INCLIVA, Endocrinology and Nutrition Department Clinic Hospital and Department of Medicine, CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Department of Farmacology, Centro de Investigación Príncipe Felipe, Avenida Menéndez Pelayo, 4, 46010 Valencia, Spain
Search for other papers by Deborah Jane Burks in
Google Scholar
PubMed
Institute of Health Research-INCLIVA, Endocrinology and Nutrition Department Clinic Hospital and Department of Medicine, CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Department of Farmacology, Centro de Investigación Príncipe Felipe, Avenida Menéndez Pelayo, 4, 46010 Valencia, Spain
Search for other papers by Herminia González-Navarro in
Google Scholar
PubMed
Introduction Patients with Metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have a shorter lifespan compared with the general population ( Zambon et al . 2009 ). They constitute a major problem to global health, and their incidence is
Search for other papers by J L Nobre in
Google Scholar
PubMed
Search for other papers by P C Lisboa in
Google Scholar
PubMed
Search for other papers by A P Santos-Silva in
Google Scholar
PubMed
Search for other papers by N S Lima in
Google Scholar
PubMed
Search for other papers by A C Manhães in
Google Scholar
PubMed
Search for other papers by J F Nogueira-Neto in
Google Scholar
PubMed
Search for other papers by A Cabanelas in
Google Scholar
PubMed
Search for other papers by C C Pazos-Moura in
Google Scholar
PubMed
Search for other papers by E G Moura in
Google Scholar
PubMed
Search for other papers by E de Oliveira in
Google Scholar
PubMed
alterations can simultaneously appear, a condition called metabolic syndrome, which presents central obesity and peripheral IR as the major components ( Weiss et al . 2004 ). Experimental and epidemiological studies show an association between exposure to
Division of Integrative Physiology, Department of Surgery, Department of Physiology
Search for other papers by Masaru Koizumi in
Google Scholar
PubMed
Search for other papers by Toshihiko Yada in
Google Scholar
PubMed
& Chrousos 2002 , Kyrou et al . 2006 ). In obesity and metabolic syndrome, excessive plasma glucocorticoid level is considered a factor that leads to diabetes ( Kyrou et al . 2006 , Dallman et al . 2007 ). Cushing's syndrome with elevated plasma